Actxa and LIF launch smart ring partnership in Indonesia

Actxa and PT LIF Indonesia have formed a strategic partnership to expand preventive health technology and personalized wellness tools in Indonesia. The collaboration debuts the LIF Core Smart Ring with AI Glucose Scan and adds a new commercial path for Actxa’s wearable health tech in a market facing rising diabetes risk.

Why it matters: - Indonesia is seeing rising demand for preventive health tools as lifestyle-related health risks grow. - Kemenkes, Indonesia’s Ministry of Health, reports more than 20 million diabetic adults and millions more prediabetic. - The partnership aims to make health data easier to access and more useful for everyday decisions. - The collaboration could broaden adoption of wearable-based wellness tracking in one of Asia’s largest consumer health markets.

What happened: - Actxa Pte. Ltd. and PT LIF Indonesia announced a strategic partnership on June 9, 2026. - The companies are co-branding a new product, the LIF Core Smart Ring with AI Glucose Scan. - LIF has been named Actxa’s exclusive integration and commercialisation partner in Indonesia. - The smart ring is now available through LIF’s official website and official marketplaces. - The device will soon be sold at LIF partner stores Erafone across Jabodetabek and Bali.

The details: - The LIF Core Smart Ring is designed for 24/7 wear and weighs less than 4 grams. - The ring is made of high-grade titanium. - The device tracks AI Glucose Scan, sleep duration, sleep stages, sleep quality, recovery trends, heart rate, blood oxygen saturation, VO₂ Max estimation, moderate-to-vigorous physical activity, daily activity and wellness trends. - The smart ring connects directly to the LIF mobile application. - LIF says the app turns health data into easy-to-understand insights on metabolism, sleep, recovery, activity and overall wellness. - The product also includes AI Glucose Scan powered by BGEM, which is designed to provide glucose-related lifestyle insights. - The official retail price is IDR 3,999,000. - Buyers can access 0% installment options for up to 12 months on participating e-commerce platforms and under partner store policies. - The companies said they previously worked with UKRIDA University on a clinical trial involving more than 800 participants. - That trial clinically validated the world’s first non-invasive Blood Glucose Evaluation and Monitoring technology behind Actxa’s AI Glucose Scan. - The product note says the LIF Core Smart Ring is a wellness tracker, its data is estimation and trend-based, and it is not intended to diagnose, treat, cure or prevent any disease. - The note also advises users to consult a medical professional about health results.

Between the lines: - The deal gives Actxa a local commercial partner with consumer reach, support infrastructure and a digital health ecosystem in Indonesia. - The launch pushes both companies beyond simple step counting and into more personalized wellness guidance. - The glucose-related feature is positioned as an education and lifestyle tool, not a medical device claim. - The partnership reflects a broader regional shift toward prevention-first health products tied to daily behavior.

What’s next: - LIF is expected to expand distribution through its digital channels and retail partners. - The companies are likely to use the smart ring launch to build adoption for AI-powered wellness insights in Indonesia. - Further product and ecosystem integrations may follow as the partnership develops.

The bottom line: - Actxa and LIF are betting that preventive health tools, local distribution and AI-driven insights can make wearable wellness products more relevant to Indonesian consumers.